Neurocrine Biosciences has entered into a $300 million accelerated share repurchase agreement with Goldman Sachs to buy back its own stock, with the transaction expected to complete by early 2025.
AI Assistant
NEUROCRINE BIOSCIENCES INC
2024
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.